Related Experiment Video
Updated: Jan 13, 2026

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
Published on: December 25, 2021
The potential of circITFG2 as a therapeutic target in lung squamous cell carcinoma
Background:
Lung squamous cell carcinoma (LUSC) is a highly aggressive malignancy with limited therapeutic options and poor patient prognosis. Emerging evidence suggests that circular RNAs (circRNAs) play critical regulatory roles in cancer progression, but their involvement in LUSC remains largely unexplored. This study aimed to investigate the functional role of circular RNA ITFG2 (circITFG2) in LUSC pathogenesis and to evaluate its potential as a novel therapeutic target.
Methods:
The expression profile of circRNAs in clinical LUSC samples was analyzed via the Arraystar human circRNA microarray, and the level of circITFG2 was validated via Arraystar circular RNA microarray chip sequencing. Functional characterization was performed through in vitro cellular assays, including proliferation, migration, and invasion experiments, while tumor growth in vivo was assessed with a xenograft mouse model. Molecular mechanisms and immunomodulatory effects were elucidated and evaluated through Western blotting, quantitative reverse-transcription polymerase chain reaction (RT-qPCR), RNA immunoprecipitation (RIP), luciferase reporter assays, and T cell-mediated natural cytotoxicity experiments.
Results:
Both bioinformatics and experimental analyses revealed that circITFG2 was significantly downregulated in LUSC tissues. Functional studies demonstrated that circITFG2 overexpression markedly suppressed LUSC cell proliferation, migration, and invasion. Xenograft experiments also showed that tumors in the circITFG2-overexpression group were significantly smaller than those in the control group. Further investigations identified integral membrane protein 2A (ITM2A) as a key downstream effector. Overexpression of circITFG2 competitively bound miR-526b-5p to upregulate ITM2A, ultimately activating the autophagy pathway to promote programmed death-ligand 1 (PD-L1) degradation and thereby enhancing antitumor immune responses.
Conclusions:
This study identifies circITFG2 as a frequently underexpressed regulatory circRNA in LUSC. Its overexpression inhibited cancer cell proliferation, migration, and invasion while reducing tumor growth in xenografts. Oe-circITFG2 competitively bound miR-526b-5p, upregulating ITM2A to activate autophagy-mediated PD-L1 degradation and enhance antitumor immunity.
Insights
Circular RNA ITFG2 (circITFG2) is underexpressed in lung squamous cell carcinoma (LUSC). Restoring circITFG2 inhibits LUSC progression and enhances antitumor immunity by regulating the ITM2A/miR-526b-5p axis.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Lung squamous cell carcinoma (LUSC) is an aggressive cancer with limited treatment options.
- Circular RNAs (circRNAs) are implicated in cancer, but their role in LUSC is understudied.
- This study investigates the function of circRNA ITFG2 (circITFG2) in LUSC.
Purpose of the Study:
- To explore the role of circITFG2 in LUSC pathogenesis.
- To assess circITFG2 as a potential therapeutic target for LUSC.
Main Methods:
- circRNA expression profiling in LUSC tissues using microarrays.
- In vitro assays (proliferation, migration, invasion) and in vivo xenograft models.
- Molecular mechanism studies including Western blotting, RT-qPCR, RIP, and luciferase assays.
Main Results:
- circITFG2 was significantly downregulated in LUSC tissues.
- Overexpression of circITFG2 suppressed LUSC cell proliferation, migration, and invasion.
- circITFG2 enhanced antitumor immunity via the miR-526b-5p/ITM2A pathway, promoting PD-L1 degradation.
Conclusions:
- circITFG2 acts as a tumor suppressor in LUSC.
- circITFG2 inhibits LUSC progression and enhances antitumor immunity.
- circITFG2 is a promising therapeutic target for LUSC.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Mitogens and the Cell Cycle